Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non–small cell lung cancer, and renal cell carcinoma

1. Luke, J.J.
2. Long, G.V.
3. Robert, C.
4. Carlino, M.S.
5. Choueiri, T.K.
6. Haas, N.B.
7. O'Brien, M.
8. Paz-Ares, L.
9. Peters, S.
10. Powles, T.
11. Leiby, M.A.
12. Lin, J.
13. Zhao, Y.
14. Krepler, C.
15. Perini, R.F.
16. Catherine Pietanza, M.
17. Samkari, A.
18. Gruber, T.
19. Ibrahim, N.
20. Eggermont, A.M.M.